Ivabradine to Improve Endothelial Function in Patients With Coronary Artery Disease

Heart Rate Reduction by IVabradine for Improvement of ENDothELial Function in Patients With Coronary Artery Disease: the RIVENDEL Study

This study evaluates the effect of ivabradine on endothelial function in patients with coronary artery disease (CAD) after complete revascularization with percutaneous coronary angioplasty (PCI). At least 30 days after PCI, patients will be randomized to receive ivabradine 5 mg twice daily or to continue with standard medical therapy.

Inclusion Criteria:

• history of stable coronary disease
• complete coronary revascularization with PCI at least 1 month prior to recruitment
• sinus rhythm
• absence of anginal symptoms

Exclusion Criteria:

• resting heart rate <60 beats per minute
• severe reduction of left ventricle ejection fraction (<40%)
• coronary artery by-pass surgery
• myocardial infarction, stroke or cerebral transient ischemic attack within the previous 6 months
• implanted pacemaker, cardioverter, or defibrillator
• sick sinus syndrome
• sinoatrial block
• congenital long QT
• complete atrioventricular block